Share ownership Altimmune, Inc.

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2025-12-05 EST			5-day change	1st Jan Change
5.240 ^USD	-1.32%		-0.38%	-27.32%

12-01	Altimmune, Inc. Announces CEO Changes	CI
12-01	Altimmune, Inc. Announces Executive Changes	CI

Share class: Altimmune, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	71,124,625	70,559,934 ( 99.21 %)	0	99.21 %

Major shareholders: Altimmune, Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 7.222 %	6,373,638	7.222 %	26 M $
BlackRock Advisors LLC 6.893 %	6,083,676	6.893 %	25 M $
STATE STREET CORPORATION 4.08 %	3,601,255	4.08 %	15 M $
Tang Capital Management LLC 2.415 %	2,131,307	2.415 %	9 M $
Geode Capital Management LLC 2.286 %	2,017,385	2.286 %	8 M $
Two Sigma Investments LP 2.263 %	1,996,848	2.263 %	8 M $
Morgan Stanley Capital Services LLC 1.689 %	1,491,049	1.689 %	6 M $
Two Sigma Advisers LP 1.618 %	1,428,400	1.618 %	6 M $
Susquehanna Securities LLC 1.557 %	1,374,182	1.557 %	6 M $
Citadel Securities GP LLC 1.453 %	1,282,014	1.453 %	5 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	36.28%
Other	6.71%
State Street Corp.	4.08%
Individuals	0.81%
Silvercrest Asset Management Group, Inc.	0.12%
Manulife Financial Corp.	0.03%
Unknown	51.97%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	45.29%
United Kingdom	1.27%
Individuals	0.81%
Australia	0.32%
Switzerland	0.1%
Ireland	0.08%
Canada	0.05%
Spain	0.04%
China	0.03%
United Arab Emirates	0.01%
Japan	0.01%

Based on 1000 largest holdings

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Companyâs wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Employees

Sector

Biotechnology & Medical Research

Calendar

03-25 - Q4 2025 Earnings Release (Projected)

More about the company